Global Migraine Drugs Market 2015-2019

偏頭痛治療薬の世界市場2015-2019

◆タイトル:Global Migraine Drugs Market 2015-2019
◆商品コード:IRTNTR5217
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年2月4日
◆ページ数:110
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、偏頭痛治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、偏頭痛治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・偏頭痛治療薬の世界市場:市場規模及び予測
・偏頭痛治療薬の世界市場:地域別分析
・市場シェア
・購買基準
・市場成長要因
・市場の課題
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Migraine
Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines.

TechNavio’s analysts forecast the Global Migraine Drugs market to grow at a CAGR of 3.54 percent over the period 2014-2019.

[Covered in this Report]
The report covers the present scenario and the growth prospects of the Global Migraine Drugs market for the period 2015–2019. The Global Migraine Drugs market can be divided into two segments: Selective Serotonin Receptor (5- HTI) Agonists/ Triptans and Ergot Alkaloids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment and prevention of migraine that are available in the market.

TechNavio’s report, the Global Migraine Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region, and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Abbott
• Allergan
• Eisai
• Endo
• GlaxoSmithKline
• Impax Laboratories
• Pfizer

[Other Prominent Vendors]
• Almirall
• Amgen
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly
• IntelGenx Technologies
• Johnson & Johnson
• Nautilus
• OptiNose
• RedHill Biopharma
• Zogenix

[Market Driver]
• Increase in Prevalence of Migraine
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Drugs
• For a full, detailed list, view our report

[Market Trend]
• Increase in Strategic Collaborations
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

07.Migraine Pipeline Snapshot

08.Migraine Pipeline Assessment

09.Market Segmentation by Therapeutic Class

10.Geographical Segmentation

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.3 Other Prominent Vendors

19.Key Vendor Analysis
19.1 Abbott Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Allergan
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue
19.2.5 Business Segmentation by Revenue 2011-2013
19.2.6 Geographical Segmentation by Revenue
19.2.7 Business Strategy
19.2.8 Key Developments
19.2.9 SWOT Analysis
19.3 Eisai
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Comparison between Revenue, Operating Income, and Net Income
19.3.4 Sales by Geography
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 Endo International
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Business Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.5 GlaxoSmithKline
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Pipeline Products
19.5.7 Business Strategy
19.5.8 Key Information
19.5.9 SWOT Analysis
19.6 Impax Laboratories
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Geographical Segmentation
19.6.6 Business Strategy
19.6.7 Recent Developments
19.6.8 SWOT Analysis
19.7 Pfizer
19.7.1 Key Facts
19.7.2 Business Overview
19.7.3 Business Segmentation by Revenue 2013
19.7.4 Business Segmentation by Revenue 2012 and 2013
19.7.5 Geographical Segmentation by Revenue
19.7.6 Business Strategy
19.7.7 Key Developments
19.7.8 SWOT Analysis

20.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Global Migraine Drugs Market 2014-2019 (US$ billion)
Exhibit 3: Migraine: Clinical Developmental Pipeline
Exhibit 4: Migraine Clinical Trials by Status
Exhibit 5: Migraine Clinical Trials by Phase
Exhibit 6: Global Migraine Drugs Market Segmentation by Therapeutic Class
Exhibit 7: Global Migraine Drugs Market Segmentation by Therapeutic Class 2014
Exhibit 8: Global Migraine Drugs Market by Geographical Segmentation 2014
Exhibit 9: Age and Gender Specific Prevalence of Migraine
Exhibit 10: Abbott Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 11: Abbott Product Portfolio 2013
Exhibit 12: Allergan Worldwide Sales 2013
Exhibit 13: Allergan Botox/Neuromodulator Sales 2013 (US$ million)
Exhibit 14: Eisai Year on Year Sales Comparison 2010-2012 (US$ billion)
Exhibit 15: Eisai Net Sales by Reporting Segment 2014
Exhibit 16: Endo International Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 17: GlaxoSmithKline Treximet Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 18: GlaxoSmithKline Treximet Year on Year Sales Comparison 2010-2012 (US$ million)
Exhibit 19: GlaxoSmithKline Imigran/Imitrex Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 20: Imapx Laboratories Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 21: Impax Laboratories Generic Products Percentage Share 2013
Exhibit 22: Pfizer Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 23: Pfizer Relpax Year on Year Sales Comparison 2010-2013 (US$ million)
Exhibit 24: Abbott Laboratories Inc.: Business Segmentation
Exhibit 25: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
Exhibit 26: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
Exhibit 27: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
Exhibit 28: Allergan: Business Segmentation
Exhibit 29: Allergan: Business Segmentation by Revenue 2013
Exhibit 30: Allergan: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 31: Allergan: Geographical Segmentation by Revenue 2013
Exhibit 32: Eisai Co. Ltd.: Comparison between Revenue, Operating Income, and Net Income 2011-2013 (US$ billion)
Exhibit 33: Eisai Co. Ltd.: Sales by Geography 2013 (US$ billion)
Exhibit 34: Endo International: Business Segmentation by Revenue 2013
Exhibit 35: Endo International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 36: Endo International: Geographical Segmentation by Revenue 2013
Exhibit 37: GlaxoSmithKline: Business Segmentation 2013
Exhibit 38: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 39: GlaxoSmithKline: Sales by Geography 2013
Exhibit 40: GlaxoSmithKline: Pipeline Products 2013
Exhibit 41: Impax Laboratories: Business Segmentation by Revenue 2013
Exhibit 42: Impax Laboratories: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 43: Impax Laboratories: Geographical Segmentation
Exhibit 44: Pfizer: Business Segmentation by Revenue 2013
Exhibit 45: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: Pfizer: Geographical Segmentation by Revenue 2013



【掲載企業】

Abbott,Allergan,Eisai,Endo,GlaxoSmithKline,Impax Laboratories,Pfize,Almirall ,Amgen ,AstraZeneca ,Boehringer Ingelheim ,Eli Lilly ,IntelGenx Technologies,Johnson & Johnson,Nautilus,OptiNose,RedHill Biopharma,Zogenix

【資料のキーワード】

偏頭痛治療薬、パイプライン、治療、製薬

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[偏頭痛治療薬の世界市場2015-2019]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆